FRTX — Fresh Tracks Therapeutics Share News
0.000.00%
Last trade - 00:00- $5.59m
- -$5.28m
- $8.01m
Brickell Biotech plunges on $10 mln share offering
Brief: Brickell Biotech Announces Proposed Underwritten Public Offering Of Common Stock
Brief: Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance On All Primary And Secondary Endpoints
Brickell Biotech rises on positive data from excessive sweating treatment trial
Brief: Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases
Brief: Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study Of Sofpironium Bromide Gel
Brickell Biotech Inc reports results for the quarter ended in June - Earnings Summary
Brief: Brickell Biotech Reports Second Quarter 2021 Financial Results And Provides Corporate Update
Brickell Biotech Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Brickell Biotech Increases Previously Announced Bought Deal Offering Of Common Stock To $7 Mln
Brief: Brickell Biotech Announces $5.0 Million Bought Deal Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Energy cos, Barnes & Noble Education, Cuentas, Pultegroup
U.S. STOCKS ON THE MOVE-ConocoPhillips, Bed Bath & Beyond, MediWound, Virgin Galactic
Brickell Biotech rises after enrolling patients in lead drug's study
Brief: Brickell Biotech Inc Says Final Patient Has Completed Phase 3 Pivotal Cardigan I Study
Brief: Brickell Biotech Announces Initiation Of A Phase 1 Study Of Sofpironium Bromide Gel In Primary Palmoplantar Hyperhidrosis Patients By Its Development Partner, Kaken Pharmaceutical In Japan
Brief: Brickell Biotech Inc Says Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brickell Biotech Inc reports results for the quarter ended in March - Earnings Summary
Brief: Brickell Biotech Posts Q1 Loss Per Share Of $0.15